Latest news with #Genus'
Yahoo
26-05-2025
- Business
- Yahoo
Institutional investors in Genus plc (LON:GNS) lost 3.3% last week but have reaped the benefits of longer-term growth
Given the large stake in the stock by institutions, Genus' stock price might be vulnerable to their trading decisions A total of 10 investors have a majority stake in the company with 51% ownership Analyst forecasts along with ownership data serve to give a strong idea about prospects for a business We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. A look at the shareholders of Genus plc (LON:GNS) can tell us which group is most powerful. With 81% stake, institutions possess the maximum shares in the company. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn). No shareholder likes losing money on their investments, especially institutional investors who saw their holdings drop 3.3% in value last week. However, the 12% one-year returns may have helped alleviate their overall losses. We would assume however, that they would be on the lookout for weakness in the future. Let's take a closer look to see what the different types of shareholders can tell us about Genus. See our latest analysis for Genus Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index. We can see that Genus does have institutional investors; and they hold a good portion of the company's stock. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Genus' historic earnings and revenue below, but keep in mind there's always more to the story. Investors should note that institutions actually own more than half the company, so they can collectively wield significant power. It looks like hedge funds own 6.7% of Genus shares. That's interesting, because hedge funds can be quite active and activist. Many look for medium term catalysts that will drive the share price higher. Wellington Management Group LLP is currently the largest shareholder, with 9.8% of shares outstanding. Meanwhile, the second and third largest shareholders, hold 7.1% and 6.7%, of the shares outstanding, respectively. We did some more digging and found that 10 of the top shareholders account for roughly 51% of the register, implying that along with larger shareholders, there are a few smaller shareholders, thereby balancing out each others interests somewhat. Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too. While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it. I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions. Our data suggests that insiders own under 1% of Genus plc in their own names. Keep in mind that it's a big company, and the insiders own UK£3.6m worth of shares. The absolute value might be more important than the proportional share. Arguably, recent buying and selling is just as important to consider. You can click here to see if insiders have been buying or selling. The general public, who are usually individual investors, hold a 11% stake in Genus. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run. It's always worth thinking about the different groups who own shares in a company. But to understand Genus better, we need to consider many other factors. To that end, you should be aware of the 1 warning sign we've spotted with Genus . If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Reuters
30-04-2025
- Business
- Reuters
UK's Genus secures FDA approval for PRP gene edit; shares soar
April 30 (Reuters) - British animal genetics company Genus (GNS.L), opens new tab on Wednesday said the U.S. Food and Drug Administration (FDA) approved its PRP gene edit under its PRRS Resistant Pig ("PRP") programme for use in the U.S. food supply chain. The gene edit is designed to provide pigs resistance to porcine reproductive and respiratory syndrome (PRRS), a disease affecting swine globally, whose symptoms include fever, respiratory distress, premature births. here. PRRS caused an estimated $1.2 billion per year in lost production in the U.S. pork industry from 2016 to 2020, an 80% increase from a decade earlier, according to an analysis published in 2024 by an Iowa State University expert. In its capital market update in November 2023, Genus had said that its PRP is resistant to prevalent PRRS strains. Genus' shares rose as much as 30% to a near six-month high, and were on track for their biggest one-day gain since December 2008. PRP won't really start affecting Genus' income statement until fiscal year 2027, but it could supercharge growth from then on, said Seb Jantet, research analyst at Panmure Liberum. As the U.S. is a net exporter of pork, the main issue for Genus is reciprocal tariffs which could reduce the ability of U.S. producers to export pork to Japan, Canada and Mexico, the brokerage said in the note. However, the company will "most likely be fine" as these countries are likely to turn to Brazil for supply, where it has a bigger market share than in the U.S., Panmure Liberum said. The company said the approval was a significant step towards PRP commercialisation in the U.S and added that it continues to make progress to secure approvals from regulators in Mexico, Canada, Japan and China.
